Positive treatment expectations are known to enhance antidepressant efficacy. Experimental placebo studies aim to provide mechanistic insights into this association, yet their findings have not been clearly linked to clinical expectation effects within individual patients. In a randomized crossover trial, 61 participants with major depressive disorder (31 women, 30 men) completed an emotion classification task… →

CONCLUSION: Our study highlights that breast cancer patients want information prior to the consultation, but patient-centered challenges can lead to non-review. When sharing pre-consult information, clinics should communicate how reviewing information can help patients feel less overwhelmed and improve their discussion with the surgeon. →

CONCLUSIONS: Vutrisiran may slow eGFR decline and is effective and well-tolerated in patients with ATTR-CM with declining renal function, including those developing CKD stage ≥4. →

CONCLUSIONS: Bimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years, emphasising its long-term value in controlling symptoms which profoundly affect patients’ experience and daily lives. →

CONCLUSIONS: BAFF inhibition in paediatric LN is associated with rebalancing of innate and adaptive immunity through enhancement of Breg function and suppression of ILC1-driven inflammation. →

CONCLUSIONS: In women with placenta praevia who underwent caesarean delivery and received prophylactic oxytocin, treatment with tranexamic acid resulted in a statistically significant yet modest reduction in the incidence of postpartum haemorrhage, with no signal of increased serious adverse events. →

As per the Rome IV criteria, a disorder of gut-brain interaction such as irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain occurring at least 1 day per week for the previous 3 months and associated changes in bowel movements (defecation, stool frequency, or stool form). These symptoms must have begun at least 6… →

CONCLUSIONS: Ensitrelvir administered to household contacts of a patient with Covid-19 within 72 hours after symptom onset in the index patient was effective in preventing Covid-19 in the contacts. (Funded by Shionogi; SCORPIO-PEP Japan Registry for Clinical Trials number, jRCT2031230124; ClinicalTrials.gov number, NCT05897541.). →